Home/Vasa Therapeutics/Mike Geremia

MG

Mike Geremia

CFO

Vasa Therapeutics

Therapeutic Areas

Cardiovascular Neuromuscular Age-related Disorders

Vasa Therapeutics Pipeline

Drug	Indication	Phase
VS-041	Heart Failure with Preserved Ejection Fraction (HFpEF)	Phase 1
Apelin Analogs	Peripheral Artery Disease (PAD), Neuromuscular Diseases, Sarcopenia	Preclinical

Leadership Team at Vasa Therapeutics

Artur Plonowski, MD, PhD

CEO, Co-Founder

Noreen Henig, MD

Derek Cole, PhD

Benjamin Pratt, PhD

SVP of Chemistry, Co-Founder

VP of Finance and Operations

View full Vasa Therapeutics profile